Compare GeneDx Holdings Corp (WGS) vs Zscaler Inc (ZS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GeneDx Holdings Corp vs Zscaler Inc — how do they compare? GeneDx Holdings Corp trades at $86.53 (market cap $2.56B), while Zscaler Inc trades at $166.4 (market cap $26.41B). The key difference: Zscaler Inc is far larger — about 10.3× GeneDx Holdings Corp's market cap, and GeneDx Holdings Corp is trading nearer its 52-week high, Zscaler Inc nearer its low. Which is the better fit depends on your goals.
| WGS | ZS | |
|---|---|---|
Market Cap | $2.56B | $26.41B |
Sector | Technology | Technology |
52-Week High | $167.51 | $336.27 |
52-Week Low | $34.51 | $118.05 |
Enterprise Value | $2.60B | $24.79B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
WGS trades at $85.87, down 0.14% today, with a bullish technical signal from moving averages and support at $84. The company reported Q2 2026 revenue of $114.4M, beating estimates, and returned to adjusted profitability early. However, net income remains negative at -$106M for 2026, with high valuation multiples like EV/EBITDA of 161.17. Recent news highlights partnerships and product launches, such as the NPC GenomeComplete initiative with Beren Therapeutics.
Outlook is mixed: strong analyst buy consensus (90.9%) and institutional interest support upside, but profitability challenges and a class action lawsuit pose risks. Revenue growth and operational improvements are key catalysts, yet high debt-to-asset ratios and negative margins require monitoring for sustained recovery.
Zscaler (ZS) trades at $161.94, down 4.63% amid bearish technical signals despite strong quarterly earnings beats. The stock shows improving fundamentals with revenue growing from $1.1B in 2022 to $2.67B in 2025, though net margins remain negative. Recent news highlights Zscaler's AI security innovations and conference presentations, while analyst consensus remains strongly bullish with a $204.88 price target representing 26% upside potential.
Zscaler presents a compelling growth story with accelerating revenue and strong enterprise adoption, though profitability challenges and elevated valuation metrics warrant caution. The stock's current weakness near support levels offers potential entry points for investors bullish on cybersecurity demand, particularly given Zscaler's leadership in zero-trust security and AI-driven threat protection capabilities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →About Zscaler Inc
Zscaler is a security-as-a-service firm that offers its customers cloud-delivered solutions for protecting user devices and data. The firm leverages its position in 150 colocation data centers to deliver traditionally appliance-based security functionality, such as firewalls and sandboxes, as a completely cloud-native platform. The firm focuses on large enterprise customers and offers two primary product suites: Zscaler Internet Access, which securely connects users to externally managed application and websites (such as Salesforce and Google), and Zscaler Private Access, which securely connects users to internally managed applications. Both product suites encompass a broad gamut of capabilities situated across the traditional security stack.
Read more on ZS →
